- Home
- TCRX vs CIGL Comparison
TCRX vs CIGL Comparison
Compare TCRX & CIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TCRX | CIGL |
|---|---|---|
| Founded | 2018 | 1997 |
| Country | United States | Singapore |
| Employees | N/A | 134 |
| Industry | Biotechnology: Pharmaceutical Preparations | Diversified Commercial Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.6M | 53.4M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | TCRX | CIGL |
|---|---|---|
| Price | $1.01 | $1.78 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | ★ 574.3K | 84.5K |
| Earning Date | 03-04-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.28 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,325,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $19.81 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 266.65 | N/A |
| 52 Week Low | $0.88 | $1.40 |
| 52 Week High | $2.57 | $25.00 |
Technical Indicators
Market Signals| Indicator | TCRX | CIGL |
|---|---|---|
| Relative Strength Index (RSI) | 45.55 | 41.37 |
| Support Level | $0.90 | $1.55 |
| Resistance Level | $1.24 | $2.28 |
| Average True Range (ATR) | 0.06 | 0.21 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 34.91 | 9.22 |
Price Performance
Historical ComparisonAbout TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
About CIGL Concorde International Group Ltd Class A Ordinary Shares
Concorde International Group Ltd is an integrated security services provider that combines physical manpower and technology to deliver effective security solutions. The company offers a range of services to enhance security and safety: (1) i-Guarding Services; (2) Man-Guarding Services; and (3) Consultancy and Training Services. Its i-Guarding Services leverages technology to increase efficiency, with a mobile platform and cluster aggregation model of a higher skillset workforce. It has two operating segments, which are (i) security services; and (ii) training school. Key revenue is generated from Security Services.